Hims House Ep 39 - Legendary Wall Street analyst David Maris on why Hims could be massive—and what could go wrong
12 snips
Jul 22, 2025 David Maris, a renowned Wall Street analyst and founder of Wall Street Beats, discusses his bullish outlook on Hims, highlighting its growth potential and recent acquisition of ZAVA. He dives into the implosion of its partnership with Novo Nordisk and the associated legal risks. Maris shares insights on Hims' expansion into Canada and its potential to become a comprehensive healthcare platform. He also examines the market dynamics of GLP-1 treatments and the implications of high short interest on Hims' stock valuation.
AI Snips
Chapters
Transcript
Episode notes
Subscriber Growth Drives Bullishness
- David Maris was attracted to HIMS because of its substantial subscriber growth across multiple therapeutic areas.
- This growth is rare at that scale and indicates a sticky business model beyond just ED drugs.
Acquisition Price Less Important Than Execution
- HIMS' acquisition of ZAVA for an estimated 3x revenue is immaterial to its current market cap.
- The bigger question is whether they can successfully manage the complexities of expansion without losing focus.
Canada Expansion Makes Strategic Sense
- HIMS expansion into Canada is easier operationally due to cultural and time zone similarities.
- It offers experience in sourcing generics ahead of the US patent expiry, providing a competitive edge.